 Michael Clay
Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lipoma | 4 | 2022 | 15 | 1.970 |
Why?
| | Biomarkers, Tumor | 8 | 2021 | 1040 | 1.860 |
Why?
| | Soft Tissue Neoplasms | 4 | 2022 | 90 | 1.140 |
Why?
| | Rhabdomyosarcoma | 4 | 2022 | 54 | 1.120 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2023 | 48 | 1.110 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 3 | 2023 | 56 | 1.090 |
Why?
| | Liposarcoma | 3 | 2023 | 26 | 0.970 |
Why?
| | Adrenocortical Carcinoma | 2 | 2023 | 47 | 0.960 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2013 | 49 | 0.840 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2013 | 76 | 0.820 |
Why?
| | DNA Methylation | 4 | 2023 | 495 | 0.810 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2016 | 309 | 0.800 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1141 | 0.690 |
Why?
| | Fibroma | 1 | 2020 | 21 | 0.680 |
Why?
| | Succinate Dehydrogenase | 1 | 2019 | 42 | 0.650 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2019 | 43 | 0.640 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2019 | 59 | 0.630 |
Why?
| | Breast Neoplasms | 3 | 2014 | 1862 | 0.610 |
Why?
| | Immunohistochemistry | 6 | 2021 | 1629 | 0.560 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2016 | 33 | 0.550 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1518 | 0.550 |
Why?
| | Gene Amplification | 2 | 2020 | 95 | 0.540 |
Why?
| | DNA Mismatch Repair | 1 | 2014 | 37 | 0.480 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 30 | 0.460 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2023 | 445 | 0.450 |
Why?
| | Neoplasms, Second Primary | 1 | 2014 | 92 | 0.440 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 59 | 0.430 |
Why?
| | Translocation, Genetic | 1 | 2013 | 94 | 0.430 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 174 | 0.410 |
Why?
| | Kidney Neoplasms | 3 | 2023 | 327 | 0.400 |
Why?
| | Wilms Tumor | 3 | 2023 | 68 | 0.400 |
Why?
| | Diagnosis, Differential | 5 | 2021 | 1342 | 0.390 |
Why?
| | Nuclear Proteins | 4 | 2021 | 591 | 0.370 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2010 | 7 | 0.360 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2011 | 27 | 0.360 |
Why?
| | Receptor, ErbB-2 | 1 | 2013 | 300 | 0.360 |
Why?
| | Myometrium | 1 | 2011 | 35 | 0.360 |
Why?
| | Anus Neoplasms | 1 | 2010 | 24 | 0.350 |
Why?
| | Li-Fraumeni Syndrome | 2 | 2021 | 11 | 0.350 |
Why?
| | Uterine Neoplasms | 1 | 2011 | 73 | 0.350 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 130 | 0.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1355 | 0.300 |
Why?
| | Humans | 39 | 2023 | 114599 | 0.300 |
Why?
| | Genomics | 3 | 2021 | 635 | 0.290 |
Why?
| | Neoplasms | 4 | 2021 | 2097 | 0.270 |
Why?
| | Female | 23 | 2023 | 59446 | 0.250 |
Why?
| | Male | 23 | 2023 | 55534 | 0.240 |
Why?
| | Young Adult | 7 | 2021 | 10452 | 0.240 |
Why?
| | Liver Neoplasms | 2 | 2019 | 506 | 0.230 |
Why?
| | Child, Preschool | 8 | 2021 | 9106 | 0.230 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 1879 | 0.230 |
Why?
| | Adamantinoma | 1 | 2023 | 5 | 0.230 |
Why?
| | Oncogene Fusion | 2 | 2020 | 9 | 0.220 |
Why?
| | X-linked Nuclear Protein | 2 | 2020 | 7 | 0.210 |
Why?
| | Meniscus | 1 | 2023 | 21 | 0.210 |
Why?
| | Infant | 10 | 2021 | 7954 | 0.210 |
Why?
| | Adult | 12 | 2023 | 30514 | 0.210 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.200 |
Why?
| | Child | 14 | 2023 | 18401 | 0.200 |
Why?
| | Neuroblastoma | 2 | 2020 | 133 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 858 | 0.200 |
Why?
| | Mutation | 4 | 2021 | 3344 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 698 | 0.190 |
Why?
| | Immunoglobulin A | 1 | 2022 | 166 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2023 | 194 | 0.190 |
Why?
| | Whole Genome Sequencing | 1 | 2021 | 94 | 0.190 |
Why?
| | In Situ Hybridization | 1 | 2021 | 292 | 0.190 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 130 | 0.190 |
Why?
| | Penetrance | 1 | 2021 | 27 | 0.190 |
Why?
| | Orthopedic Procedures | 1 | 2023 | 208 | 0.180 |
Why?
| | Adolescent | 8 | 2021 | 17827 | 0.180 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 154 | 0.180 |
Why?
| | Introns | 1 | 2021 | 227 | 0.180 |
Why?
| | Germ Cells | 1 | 2021 | 57 | 0.180 |
Why?
| | Myofibroma | 1 | 2020 | 4 | 0.180 |
Why?
| | Computational Biology | 2 | 2021 | 530 | 0.180 |
Why?
| | Exons | 1 | 2021 | 302 | 0.180 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2020 | 4 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 64 | 0.180 |
Why?
| | Tandem Repeat Sequences | 2 | 2017 | 17 | 0.180 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6344 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 35 | 0.180 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 25 | 0.180 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2020 | 7 | 0.170 |
Why?
| | Receptor, trkA | 1 | 2020 | 16 | 0.170 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 213 | 0.170 |
Why?
| | Phenotype | 2 | 2020 | 2796 | 0.170 |
Why?
| | Phthalazines | 1 | 2020 | 38 | 0.170 |
Why?
| | Lamin Type A | 1 | 2020 | 40 | 0.170 |
Why?
| | Middle Aged | 8 | 2021 | 26705 | 0.170 |
Why?
| | Cell Nucleus | 2 | 2020 | 554 | 0.170 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.170 |
Why?
| | Aged | 6 | 2021 | 19056 | 0.170 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 68 | 0.170 |
Why?
| | Clonal Evolution | 1 | 2019 | 27 | 0.170 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 246 | 0.170 |
Why?
| | Cell Dedifferentiation | 1 | 2019 | 28 | 0.160 |
Why?
| | Mutation, Missense | 1 | 2021 | 293 | 0.160 |
Why?
| | DNA Damage | 1 | 2021 | 351 | 0.160 |
Why?
| | Mice | 8 | 2022 | 14859 | 0.160 |
Why?
| | Prognosis | 3 | 2022 | 3327 | 0.160 |
Why?
| | Rhabdoid Tumor | 1 | 2019 | 80 | 0.160 |
Why?
| | Muscle Neoplasms | 1 | 2018 | 8 | 0.160 |
Why?
| | Psychomotor Disorders | 1 | 2018 | 17 | 0.160 |
Why?
| | Neuroendocrine Tumors | 1 | 2019 | 85 | 0.160 |
Why?
| | Patella | 1 | 2018 | 22 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 187 | 0.150 |
Why?
| | Scrotum | 1 | 2018 | 23 | 0.150 |
Why?
| | Codon, Nonsense | 1 | 2018 | 37 | 0.150 |
Why?
| | Immunophenotyping | 1 | 2019 | 273 | 0.150 |
Why?
| | ErbB Receptors | 2 | 2022 | 554 | 0.150 |
Why?
| | Tumor Burden | 2 | 2017 | 259 | 0.150 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2018 | 395 | 0.150 |
Why?
| | Craniofacial Abnormalities | 1 | 2018 | 59 | 0.150 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 48 | 0.150 |
Why?
| | Histone Acetyltransferases | 1 | 2018 | 51 | 0.150 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 551 | 0.150 |
Why?
| | Heterozygote | 1 | 2018 | 251 | 0.150 |
Why?
| | Fused Kidney | 1 | 2017 | 1 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 6 | 0.140 |
Why?
| | Sarcoma, Clear Cell | 1 | 2017 | 8 | 0.140 |
Why?
| | Fibrosarcoma | 1 | 2017 | 20 | 0.140 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2016 | 6 | 0.140 |
Why?
| | Intellectual Disability | 1 | 2018 | 128 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2015 | 2761 | 0.140 |
Why?
| | Genetic Variation | 1 | 2021 | 870 | 0.140 |
Why?
| | Hemangioendothelioma | 1 | 2016 | 12 | 0.140 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2016 | 4 | 0.140 |
Why?
| | Ectodermal Dysplasia | 1 | 2016 | 15 | 0.130 |
Why?
| | Scalp | 1 | 2016 | 29 | 0.130 |
Why?
| | Troponin | 1 | 2015 | 44 | 0.130 |
Why?
| | Sarcoma, Kaposi | 1 | 2016 | 68 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 636 | 0.130 |
Why?
| | Mismatch Repair Endonuclease PMS2 | 1 | 2014 | 6 | 0.120 |
Why?
| | MutL Protein Homolog 1 | 1 | 2014 | 9 | 0.120 |
Why?
| | Clone Cells | 2 | 2017 | 247 | 0.120 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 135 | 0.120 |
Why?
| | MutS Homolog 2 Protein | 1 | 2014 | 12 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2084 | 0.120 |
Why?
| | DNA Repair Enzymes | 1 | 2014 | 22 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1001 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 1796 | 0.110 |
Why?
| | Repressor Proteins | 1 | 2017 | 366 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2014 | 153 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 372 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 608 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 663 | 0.110 |
Why?
| | Algorithms | 1 | 2020 | 1466 | 0.110 |
Why?
| | Breast | 1 | 2013 | 139 | 0.110 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 192 | 0.100 |
Why?
| | Trastuzumab | 1 | 2013 | 89 | 0.100 |
Why?
| | Mastectomy | 1 | 2013 | 99 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1691 | 0.100 |
Why?
| | Risk Factors | 2 | 2015 | 8624 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 367 | 0.100 |
Why?
| | Disease Management | 1 | 2015 | 560 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2019 | 979 | 0.100 |
Why?
| | Kidney | 1 | 2018 | 1187 | 0.100 |
Why?
| | Disease Models, Animal | 1 | 2021 | 3531 | 0.100 |
Why?
| | Animals | 10 | 2023 | 31692 | 0.100 |
Why?
| | Epithelioid Cells | 1 | 2011 | 8 | 0.090 |
Why?
| | Genomic Imprinting | 2 | 2023 | 32 | 0.090 |
Why?
| | Penile Neoplasms | 1 | 2010 | 7 | 0.090 |
Why?
| | Critical Illness | 1 | 2015 | 644 | 0.090 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2010 | 42 | 0.090 |
Why?
| | DNA, Neoplasm | 1 | 2010 | 157 | 0.090 |
Why?
| | Papillomaviridae | 1 | 2010 | 101 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1121 | 0.090 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1167 | 0.080 |
Why?
| | Mice, Nude | 2 | 2021 | 630 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2279 | 0.080 |
Why?
| | Liver | 1 | 2016 | 1633 | 0.080 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 385 | 0.080 |
Why?
| | Databases, Factual | 1 | 2013 | 1124 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1313 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2017 | 12541 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 216 | 0.070 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 520 | 0.070 |
Why?
| | DNA | 2 | 2023 | 1351 | 0.070 |
Why?
| | Rodent Control | 1 | 1985 | 2 | 0.060 |
Why?
| | Leptospira interrogans | 1 | 1985 | 4 | 0.060 |
Why?
| | Leptospirosis | 1 | 1985 | 6 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 577 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2010 | 795 | 0.060 |
Why?
| | Diaphyses | 1 | 2023 | 13 | 0.060 |
Why?
| | Occupational Diseases | 1 | 1985 | 128 | 0.060 |
Why?
| | Ulna | 1 | 2023 | 25 | 0.060 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 18 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 40 | 0.050 |
Why?
| | Fibula | 1 | 2023 | 41 | 0.050 |
Why?
| | Prospective Studies | 1 | 2014 | 6214 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 133 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2023 | 152 | 0.050 |
Why?
| | Drug Resistance | 1 | 2022 | 158 | 0.050 |
Why?
| | Muscle Development | 1 | 2022 | 98 | 0.050 |
Why?
| | Gene Knock-In Techniques | 1 | 2021 | 46 | 0.050 |
Why?
| | Brazil | 1 | 2021 | 89 | 0.050 |
Why?
| | Myositis Ossificans | 1 | 2020 | 6 | 0.050 |
Why?
| | Periosteum | 1 | 2020 | 10 | 0.050 |
Why?
| | Fasciitis | 1 | 2020 | 10 | 0.050 |
Why?
| | Complement Activation | 1 | 2023 | 340 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 430 | 0.040 |
Why?
| | Dasatinib | 1 | 2020 | 46 | 0.040 |
Why?
| | Freezing | 1 | 2020 | 84 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2020 | 135 | 0.040 |
Why?
| | Autoantigens | 1 | 2022 | 396 | 0.040 |
Why?
| | Etoposide | 1 | 2019 | 148 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 135 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 201 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 2019 | 72 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 314 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 242 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 5040 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1760 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 179 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 41 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 770 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2018 | 43 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 849 | 0.040 |
Why?
| | Signal Transduction | 2 | 2023 | 4509 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 4894 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 430 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2017 | 5 | 0.040 |
Why?
| | Epigenomics | 1 | 2018 | 101 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2017 | 58 | 0.040 |
Why?
| | Bortezomib | 1 | 2017 | 41 | 0.040 |
Why?
| | Genes, p53 | 1 | 2017 | 61 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 531 | 0.040 |
Why?
| | Vincristine | 1 | 2017 | 98 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2017 | 80 | 0.040 |
Why?
| | Heterografts | 1 | 2017 | 117 | 0.040 |
Why?
| | Camptothecin | 1 | 2017 | 96 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2017 | 88 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 96 | 0.030 |
Why?
| | Family | 1 | 2020 | 589 | 0.030 |
Why?
| | Fibroblasts | 1 | 2021 | 837 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2017 | 123 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 1947 | 0.030 |
Why?
| | beta Catenin | 1 | 2017 | 219 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 347 | 0.030 |
Why?
| | Indoles | 1 | 2017 | 304 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1345 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 336 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 951 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 747 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 376 | 0.030 |
Why?
| | Pyrazoles | 1 | 2017 | 362 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2362 | 0.030 |
Why?
| | Leukocyte Transfusion | 1 | 1994 | 2 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 993 | 0.030 |
Why?
| | Granulocytes | 1 | 1994 | 77 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2565 | 0.030 |
Why?
| | Mycoses | 1 | 1994 | 66 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 3881 | 0.030 |
Why?
| | Neutropenia | 1 | 1994 | 125 | 0.030 |
Why?
| | Aging | 1 | 2023 | 1618 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 1994 | 239 | 0.030 |
Why?
| | Proteomics | 1 | 2018 | 835 | 0.030 |
Why?
| | Acute Coronary Syndrome | 1 | 2015 | 253 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 555 | 0.030 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 373 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 2710 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4689 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2015 | 776 | 0.020 |
Why?
| | Registries | 1 | 2017 | 1767 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9084 | 0.020 |
Why?
| | Biomarkers | 1 | 2015 | 3405 | 0.020 |
Why?
| | Michigan | 1 | 1985 | 96 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 1985 | 72 | 0.020 |
Why?
| | United States | 1 | 2015 | 12167 | 0.010 |
Why?
| | Rats | 1 | 1985 | 4958 | 0.010 |
Why?
| | Aspergillus | 1 | 1994 | 16 | 0.010 |
Why?
| | Candidiasis | 1 | 1994 | 51 | 0.010 |
Why?
| | Candida albicans | 1 | 1994 | 50 | 0.010 |
Why?
|
|
Clay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|